The markets are looking ahead to oral arguments at the Supreme Court on Wednesday about whether President Trump's reciprocal tariffs are legal. Oral arguments may provide hints about how the Supreme Court might rule. The Supreme Court is expected to issue its ruling by late this year or early in 2026. Lower courts have already ruled that Mr. Trump's reciprocal tariffs are illegal, finding they are based on a specious claim of emergency authority under the 1977 International Emergency Economic Powers Act. If ...

Key Takeaways Sarepta posted an adjusted Q3 loss of $0.13 per share, missing estimates and reversing last year's profit.Revenue fell 15% to $399.4M as Elevidys sales dropped 27% after halted shipments to non-ambulatory patients.The ESSENCE study failed its main goal, sparking a 35% stock plunge and concerns over Sarepta's DMD programs.Sarepta Therapeutics, Inc. (SRPT) reported third-quarter 2025 adjusted loss of 13 cents per share against the Zacks Consensus Estimate for earnings per share (EPS) of one cent ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with placebo in 225 patients aged 6-13 years with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping.The treatment favored placebo; however, the observed difference of 0.05 steps/second in least-squares means (LSM) did not reach statistical significance (P=0.309) for the primary endpoint, the 4-step ascend velocity at 96 weeks.Also Read: What’ ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin Shkreli said he still likes the stock. SRPT stock is crashing. See the real-time price action here. Sarepta's Phase 3 ESSENCE study, which tested Amondys 45 and Vyondys 53 as treatments for Duchenne muscular dystrophy, failed to meet its primary endpoint of showing clear benefit over placebo. Read Next: Michae ...

The markets are looking ahead to oral arguments at the Supreme Court this Wednesday about whether President Trump's reciprocal tariffs are legal. Oral arguments may provide hints about how the Supreme Court might rule. The Supreme Court is expected to issue its ruling by late this year or early in 2026. Lower courts have already ruled that Mr. Trump's reciprocal tariffs are illegal, finding they are based on a specious claim of emergency authority under the 1977 International Emergency Economic Powers Act. ...

(Reuters) -Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and weak forecast for its top selling gene therapy raised concerns about the strength of the company's portfolio. The trial setback compounds Sarepta's woes as it is already facing scrutiny and restrictions related to its top-selling gene therapy, Elevidys, following deaths of two patients earlier this year. Sarepta was testing its therapies, Amondys 45 and Vyondys 53, in a tri ...

TESLA WATCH: Elon Musk Pay Deal In Focus Sarepta stock lost almost a third of its value Tuesday on a "mixed bag" third-quarter report that included two drug failures, delayed test results and a sales beat. Sarepta Therapeutics (SRPT) said late Monday it's planning to ask the Food and Drug Administration to grant a traditional approval to Amondys 45 and Vyondys 53 based on evidence of "positive risk-benefits" in treating Duchenne muscular dystrophy. Both drugs are on the market with accelerated approvals, bu ...

The markets are looking ahead to oral arguments at the Supreme Court this Wednesday about whether President Trump's reciprocal tariffs are legal. Oral arguments may provide hints about how the Supreme Court might rule. The Supreme Court is expected to issue its ruling by late this year or early in 2026. Lower courts have already ruled that Mr. Trump's reciprocal tariffs are illegal, finding they are based on a specious claim of emergency authority under the 1977 International Emergency Economic Powers Act. ...

Sarepta Therapeutics (NasdaqGS:SRPT) Q3 2025 Earnings Call November 03, 2025 04:30 PM ET Speaker1Good afternoon and welcome to Sarepta's third quarter 2025 financial results conference call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, Director of Investor Relations. Please go ahead.Speaker7Thank you. Thank you all for joining today's call. Earlier this afternoon, we released our financial results for the third quarter of 2025. The press release an ...

财务业绩 - 第二季度调整后每股收益为202美元 远超Zacks共识预期的111美元 主要得益于超预期的合作收入和较低运营开支[1] - 总营收达6111亿美元 同比增长68% 超出Zacks共识预期的5295亿美元[2] - 产品收入达5131亿美元 同比增长42% 主要受Elevidys销售增长驱动[3] 产品收入构成 - 三款PMO疗法产品收入2313亿美元 同比下降3% 但仍超出Zacks共识预期的2283亿美元[4] - 基因疗法Elevidys销售额达2819亿美元 同比大幅增长132% 超出Zacks共识预期的2779亿美元[4] - 合作与其他收入达9800万美元 包含罗氏支付的6350万美元日本批准里程碑款项及2700万美元合同生产收入[5] 运营成本 - 调整后研发费用1817亿美元 同比增长18% 主要因Elevidys临床材料费用增加及1300万美元Brammer Bio和解费用[7] - 调整后销售与管理费用1134亿美元 同比增长7% 主要因Elevidys营销相关的专业服务费用增加[7] 业务发展与合作 - 与罗氏2019年达成授权协议 罗氏拥有Elevidys在美国以外市场的独家商业化权利[6] - 从罗氏获得510万美元非美国地区Elevidys销售特许权使用费[5] 监管与安全事件 - 三例患者死亡与基因疗法相关 两例涉及Elevidys 一例涉及实验性LGMD疗法 均与非 ambulant 患者相关且与AAVrh74载体有关[13] - FDA上周批准Elevidys用于ambulant患者 公司已恢复产品发货[15] - 正在制定增强免疫抑制方案的新协议 以提高非ambulant患者用药安全性[18] 战略调整与重组 - 启动重组计划 预计从2026年起每年节省4亿美元[19] - 裁员36%约500名员工 预计每年节省12亿美元[19] - 重新调整研发管线 暂停多数LGMD项目 重点发展siRNA项目[20] 研发管线进展 - 从Arrowhead收购四个临床阶段项目 包括FSHD、IPF、DM1和SCA2适应症[21] - FSHD和DM1项目初步数据预计在年底前公布[21] 业绩指引 - 预计2025年从三款PMO疗法获得9亿美元收入[12] - 维持Elevidys在ambulant患者群体最低5亿美元年收入预期[11]